Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety results

Authors: A. Castagna, V. Spagnuolo, L. Galli, C. Vinci, S. Nozza, E. Carini, A. D'Arminio Monforte, F. Montella, A. Antinori, A. Di Biagio, S. Rusconi, A. Lazzarin, C. Viscoli, A. Parisini, R. Prinapori, F. Mazzotta, S. Lo Caputo, M. Di Pietro, C. Tincati, T. Bini, E. Merlini, M. Puoti, M. Moioli, M. Montella, F. di Sora, A. Ammassari, S. Ottou, R. Cauda, S. di Giambenedetto, M. Galli, M. Franzetti, G. Rizzardini, A. Capetti, F. Cossarini, N. Gianotti, C. Mussini, G. Guaraldi

Source: AIDS. 28:2269-2279

Subject Terms: Adult, Male, 0301 basic medicine, Drug-Related Side Effects and Adverse Reactions, Anti-HIV Agents, Pyridines, Atazanavir Sulfate, HIV Infections, Simplification, 03 medical and health sciences, Atazanavir/ritonavir, HIV, Nucleos(t)ide reverse transcriptase inhibitors toxicity, Protease inhibitor monotherapy, Virological suppression, Antiretroviral Therapy, Highly Active, Female, HIV-1, Humans, Middle Aged, Oligopeptides, Ritonavir, Treatment Outcome, Viral Load, antiretroviral therapy, simplification, monotherapy, atazanavir, 0303 health sciences, 3. Good health, 13. Climate action

File Description: application/msword; application/pdf

Access URL: http://hdl.handle.net/2434/251506
https://pubmed.ncbi.nlm.nih.gov/25058680
https://pubmed.ncbi.nlm.nih.gov/25058680/
https://europepmc.org/article/MED/25058680
https://moh-it.pure.elsevier.com/en/publications/simplification-to-atazanavirritonavir-monotherapy-for-hiv-1-treat
https://www.ncbi.nlm.nih.gov/pubmed/25058680/
https://air.unimi.it/handle/2434/251506

Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety results

Authors: Castagna, A., Spagnuolo, V., Galli, Lavinia Maddalena, Vinci, C., Nozza, S., Carini, Elettra, Monforte, A. D., Montella, Francesco, Antinori, Armando, Di Biagio, Anna, Rusconi, S., Lazzarin, A., Viscoli, C., Parisini, A., Prinapori, R., Mazzotta, F., Lo Caputo, S., Di Pietro, Maria Luisa, D'Arminio-Monforte, A., Tincati, C., Bini, T., Merlini, E., Puoti, M., Moioli, M., Montella, M., Di Sora, Fiorella, Ammassari, A., Ottou, S., Cauda, Roberto, Di Giambenedetto, Simona, Galli, M., Franzetti, M., Rizzardini, G., Capetti, A., Cossarini, F., Gianotti, N., Mussini, C., Guaraldi, G., Galli L., Carini E., Montella F., Antinori A. (ORCID:0000-0002-6019-2417), Di Biagio A., Di Pietro M. (ORCID:0000-0002-3893-8788), Di Sora F., Cauda R. (ORCID:0000-0002-1498-4229), Di Giambenedetto S. (ORCID:0000-0001-6990-5076)

Index Terms: Atazanavir/ritonavir, HIV, Nucleos(t)ide reverse transcriptase inhibitors toxicity, Protease inhibitor monotherapy, Simplification, Virological suppression, Adult, Anti-HIV Agents, Antiretroviral Therapy, Highly Active, Atazanavir Sulfate, Drug-Related Side Effects and Adverse Reactions, Female, HIV Infections, HIV-1, Humans, Male, Middle Aged, Oligopeptides, Pyridines, Ritonavir, Treatment Outcome, Viral Load, Settore MED/17 - MALATTIE INFETTIVE, info:eu-repo/semantics/article

URL: http://hdl.handle.net/10807/193897
info:eu-repo/semantics/altIdentifier/pmid/25058680
info:eu-repo/semantics/altIdentifier/wos/WOS:000342231900010
volume:28
issue:15
firstpage:2269
lastpage:2279
numberofpages:11
issueyear:2014
journal:AIDS